Side effects are rare, generally mild, and may include occasional injection-site irritation, or mild nausea
Mean weight reductions were greater with all cagrilintide doses (roughly 6.0% to 10.8%) than with placebo (3.0%), and the top 4.5 mg dose modestly out-performed the active comparator, once-daily liraglutide 3.0 mg (10.8% vs 9.0%)
these included 15 pharmacokinetic (PK) studies [13,14,15,16,17,18,19,20,21,22,23,24,25,26,27], one pharmacodynamic (PD) study [28], one review with detailed PK data not elsewhere published [29], three conference abstracts [30,31,32], one case report [33] and one case series [34] (Fig
Campbell (CRUK Scotland Institute) for their scientific discussions and input in the revisions of this work